Optimize drug therapy and monitor patient adherence.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.1 mL)
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: 6 weeks; Refrigerated: 6 weeks; Frozen: 11 months
|No||Mycophenolic Acid||1.0 - 3.5 µg/mL||Greater than 25.0 µg/mL|
|No||Mycophenolic Acid Glucuronide||35.0-100.0 µg/mL||Not well established|
The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. A proposed therapeutic range is 1.0-3.5 µg/mL for a 2 g/day dose. A 3 g/day dose may have plasma concentrations up to 5.0 µg/mL. Trough concentrations between 2.0 and 4.0 µg/mL have been suggested to maximize efficacy and minimize adverse effects. Mycophenolic acid glucuronide is an inactive metabolite and a range of 35.0-100.0 µg/mL indicates normal metabolism. During the first two weeks of transplantation, mycophenolic acid glucuronide concentrations are typically 100 - 250 µg/mL. Adverse effects of toxicity include abdominal pain, peripheral edema, cardiac abnormalities, hypertension and electrolyte disturbances.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0090213||Mycophenolic Acid by HPLC-MS/MS||55806-4|
|2010110||Mycophenolic Acid Glucuronide||55807-2|
- CellCept MPA